Clinical Neuroscience Solutions, Inc.

The trials here

What the 24 trials at this site are about, from their registry records.

Conditions

• Depression10 trials
• Migraine3 trials
• Alzheimer disease2 trials
• Atopic dermatitis (eczema)2 trials
• High blood pressure2 trials
• Bipolar disorder1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Obesity1 trial
• Obstructive sleep apnoea1 trial
• Osteoarthritis1 trial

Phase

• Phase 212 trials
• Phase 311 trials
• Phase 2/31 trial

Status

• Completed11 trials
• Active, not recruiting4 trials
• Recruiting3 trials
• Terminated3 trials
• Enrolling by invitation2 trials
• Suspended1 trial

Lead sponsor

• Pfizer4 trials
• Biohaven Therapeutics Ltd.2 trials
• Cybin IRL Limited2 trials
• Mineralys Therapeutics Inc.2 trials
• ACADIA Pharmaceuticals Inc.1 trial
• and 13 more

Running trials

• Recruiting

  Study of EVO756 in Adults With Migraine

  NCT07616128· Phase 2· Evommune, Inc.· Source

  Contact: Nichole Baio

• Recruiting

  ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

  NCT07284667· Phase 2· ACADIA Pharmaceuticals Inc.· Source

  Contact: Sandy Filosi

• Enrolling by invitation

  Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND)

  NCT06605105· Phase 3· Cybin IRL Limited· Source

• Recruiting

  Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder

  NCT06547489· Phase 2· Syndeio Biosciences, Inc· Source

  Contact: Karen Raudibaugh

• Active, not recruiting

  A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

  NCT06625060· Phase 2· Ipsen· Source

• Enrolling by invitation

  Continuation Protocol for Obstructive Sleep Apnea (OSA)

  NCT06566820· Phase 3· Apnimed· Source

• Active, not recruiting

  Psilocybin for Major Depressive Disorder (MDD)

  NCT06308653· Phase 3· Usona Institute· Source

• Active, not recruiting

  A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

  NCT05995964· Phase 2· Pfizer· Source

• Active, not recruiting

  Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension

  NCT05968430· Phase 3· Mineralys Therapeutics Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Depression3 recruiting
• Migraine1 recruiting
• Obstructive sleep apnoea1 recruiting

Closed trials

• Completed

  Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

  NCT06836063· Phase 2· Suven Life Sciences Limited· Source

• Completed

  "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"

  NCT06564818· Phase 3· Cybin IRL Limited· Source

• Completed

  Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

  NCT06423781· Phase 2· Biohaven Therapeutics Ltd.· Source

• Completed

  Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

  NCT06419608· Phase 2· Biohaven Therapeutics Ltd.· Source

• Completed

  A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

  NCT05882045· Phase 3· Eli Lilly and Company· Source

• Completed

  A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

  NCT05769608· Phase 2· Mineralys Therapeutics Inc.· Source

• Completed

  Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee

  NCT05449132· Phase 3· Grünenthal GmbH· Source

• Completed

  Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder

  NCT05536414· Phase 2· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Completed

  A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD

  NCT05113771· Phase 2· Denovo Biopharma LLC· Source

• Terminated

  A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).

  NCT05227209· Phase 3· Sumitomo Pharma America, Inc.· Source

• Terminated

  A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

  NCT04804033· Phase 2/3· Pfizer· Source

• Completed

  Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

  NCT04321031· Phase 2· Pfizer· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Biogen· Source

• Completed

  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822· Phase 3· Pfizer· Source